Department of Internal Medicine, Yale Liver Center, Section of Digestive Diseases, Yale University School of Medicine, New Haven, Connecticut, USA.
Clin Pharmacol Ther. 2012 Sep;92(3):294-305. doi: 10.1038/clpt.2012.103. Epub 2012 Aug 1.
Chronic hepatitis C infection remains a major global public health burden associated with substantial morbidity and mortality. Recent advances in antiviral therapy with the US Food and Drug Administration (FDA) approval of the oral protease inhibitors boceprevir and telaprevir introduce a new era of treatment for hepatitis C based on directly acting antiviral agents, which are associated with significant improvements in viral eradication rates in combination with pegylated interferon plus ribavirin. Newer classes targeting the hepatitis C virus (HCV) protease, polymerase, NS5A, and other components of the viral genome demonstrate great promise to further enhance viral eradication with superior efficacy, improved tolerability, shorter duration of therapy, and diminished requirement for interferon. Current and future strategies for HCV pharmacotherapy are reviewed.
慢性丙型肝炎感染仍然是一个重大的全球公共卫生负担，与大量的发病率和死亡率有关。随着美国食品和药物管理局（FDA）批准口服蛋白酶抑制剂博赛泼维（boceprevir）和特拉泼维（telaprevir），抗病毒治疗取得了新的进展，为丙型肝炎的治疗带来了一个新的时代，这些药物基于直接作用抗病毒药物，与聚乙二醇干扰素加利巴韦林联合使用时，病毒清除率显著提高。针对丙型肝炎病毒（HCV）蛋白酶、聚合酶、NS5A 和病毒基因组其他成分的新型药物具有很大的应用前景，可以进一步提高疗效，提高耐受性，缩短治疗时间，减少对干扰素的需求，从而进一步提高病毒清除率。对丙型肝炎药物治疗的当前和未来策略进行了综述。
